^
Association details:
| Biomarker: | RET-PTC1 rearrangement |
|---|---|
| Cancer: | Thyroid Gland Papillary Carcinoma |
| Drug: | Cometriq (cabozantinib capsule) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells
Excerpt:
...compare the efficiency of four recently developed TK inhibitors, XL184, vandetanib, sunitinib, and axitinib, using three cell lines: MTC-TT reported to be derived from a sporadic MTC expressing a C634W RET mutation, MZ-CRC-1 derived from a patient with metastatic sporadic MTC expressing an M918T RET mutation, and TPC-1 derived from a patient with PTC expressing a RET/PTC-1 rearrangement....XL184 being the most potent inhibitor in MEN2A and PTC and vandetanib the most effective in MEN2B in vitro.
DOI:
https://doi.org/10.1210/jc.2010-2381
